Evidence map›Paper›PMID 36091045›Full record

ArticleFrontiers in immunology2022

Pharmacological activation of the C5a receptor leads to stimulation of the β-adrenergic receptor and alleviates cognitive impairment in a murine model of familial Alzheimer's disease.

Eleni Fella, Revekka Papacharalambous, Demos Kynigopoulos, Maria Ioannou, Rita Derua, Christiana Christodoulou, Myrto Stylianou, Christos Karaiskos, Alexia Kagiava, Gerasimou Petroula and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Eleni FellaNeuropathology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Revekka PapacharalambousNeuromuscular Disorders Center, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Demos KynigopoulosNeuropathology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Maria IoannouNeuropathology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Rita DeruaLaboratory of Protein Phosphorylation and Proteomics, Katholieke Universiteit Leuven, Leuven, Belgium.
Christiana ChristodoulouNeuroepidemiology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Myrto StylianouBioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Christos KaraiskosNeuroscience Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Alexia KagiavaNeuroscience Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Gerasimou PetroulaMolecular Haematology-Oncology, The Karaiskakio Foundation, Nicosia, Cyprus.
Chryso PieridesThe Center for the Study of Haematological Malignancies, Nicosia, Cyprus.
Maria KyriakouThe Center for the Study of Haematological Malignancies, Nicosia, Cyprus.
Laura KoumasThe Center for the Study of Haematological Malignancies, Nicosia, Cyprus.
Paul CosteasMolecular Haematology-Oncology, The Karaiskakio Foundation, Nicosia, Cyprus.
Elena PanayiotouNeuropathology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Cyprus Institute of Neurology and Genetics · CYCenter for the Study of Childhood and Adolescence · CYKU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease of the brain causing either familial or sporadic dementia. We have previously administered the modified C5a receptor agonist (EP67) for a short period to a transgenic mouse model of AD (5XFAD) and have observed not only reduction in β-amyloid deposition and gliosis but also improvement in cognitive impairment. Inquiring, however, on the effects of EP67 in an already heavily burdened animal, thus representing a more realistic scenario, we treated 6-month-old 5XFAD mice for a period of 14 weeks. We recorded a significant decrease in both fibrillar and pre-fibrillar β-amyloid as well as remarkable amelioration of cognitive impairment. Following proteomic analysis and pathway association, we postulate that these events are triggered through the upregulation of β-adrenergic and GABAergic signaling. In summary, our results reveal how inflammatory responses can be employed in inducing tangible phenotype improvements even in advanced stages of AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionOligopeptidesReceptor, Anaphylatoxin C5aReceptors, Adrenergic, betaAnimalsDisease Models, AnimalMiceMice, TransgenicProteomicsC5ar1 protein, mouseOligopeptidesReceptor, Anaphylatoxin C5aReceptors, Adrenergic, betatyrosyl-seryl-phenylalanyl-lysyl-aspartyl-methionyl-prolyl-N-methyleucyl-alanyl-arginineAlzheimer’s diseaseC5a receptorEP67GABAβ-adrenergicβ-amyloid

Identifiers

PMID36091045
PMCPMC9462583
OpenAlexW4293206546

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.